Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Evotec Se (EVO)

Evotec Se (EVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,998,940
  • Shares Outstanding, K 350,824
  • Annual Sales, $ 572,210 K
  • Annual Income, $ 7,140 K
  • 60-Month Beta 0.95
  • Price/Sales 10.10
  • Price/Cash Flow 95.93
  • Price/Book 5.89
Trade EVO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.09
  • Number of Estimates 2
  • High Estimate 0.13
  • Low Estimate 0.06
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.26 +3.14%
on 01/24/22
24.00 -17.19%
on 12/30/21
-2.75 (-12.16%)
since 12/23/21
3-Month
19.26 +3.14%
on 01/24/22
25.77 -22.89%
on 10/25/21
-5.85 (-22.74%)
since 10/21/21
52-Week
17.07 +16.42%
on 03/12/21
26.57 -25.22%
on 10/21/21
+1.74 (+9.61%)
since 01/22/21

Most Recent Stories

More News
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases

- COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS - LILLY HAS THE RIGHT...

EVTCY : 22.9600 (-0.04%)
EVO : 19.87 (-0.40%)
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic

- EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 - EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY...

EVOTF : 39.0300 (-18.84%)
EVT : 26.75 (-1.22%)
EVO : 19.87 (-0.40%)
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,...

EVO : 19.87 (-0.40%)
CMLTU : 8.87 (-6.53%)
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

- EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM - PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND...

EVTCY : 22.9600 (-0.04%)
EVO : 19.87 (-0.40%)
CMLTU : 8.87 (-6.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 20.73
2nd Resistance Point 20.31
1st Resistance Point 20.09
Last Price 19.87
1st Support Level 19.46
2nd Support Level 19.04
3rd Support Level 18.82

See More

52-Week High 26.57
Fibonacci 61.8% 22.94
Fibonacci 50% 21.82
Fibonacci 38.2% 20.70
Last Price 19.87
52-Week Low 17.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar